Adaptive Biotechnologies vs CRISPR Therapeutics
Adaptive Biotechnologies (ADPT), health care, and CRISPR Therapeutics (CRSP), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Adaptive Biotechnologies is worth $4.6B on the stock market and CRISPR Therapeutics $3.9B: Adaptive Biotechnologies is valued at 18% more. Adaptive Biotechnologies's operating margin in its latest fiscal year was -20.6% and CRISPR Therapeutics's -18934%. Over the past year Adaptive Biotechnologies's share price has moved +103% and CRISPR Therapeutics's -24.5%.
Key facts
- Adaptive Biotechnologies market value
- $4.6B
- CRISPR Therapeutics market value
- $3.9B
- Adaptive Biotechnologies revenue
- $277MFY to 2025-12-31
- CRISPR Therapeutics revenue
- $3.5MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Adaptive Biotechnologies | CRISPR Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.6Bhigher | $3.9Blower |
| Revenue | $277Mhigher | $3.5Mlower |
| Earnings | -$59.5Mhigher | -$581.6Mlower |
| Employees | 624 | — |
| Total assets | $512.7Mlower | $2.3Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | 16.7lower | 1110higher |
| P/B | 26.1 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | -20.6%higher | -18934%lower |
| Balance sheet | ||
| Net assets | $218.8Mlower | $1.9Bhigher |
| Total liabilities | $287.7Mlower | $343.4Mhigher |
| Total debt | $131.2M | — |
| Cash on hand | $70.5Mlower | $347.6Mhigher |
| Price change | ||
| Today | +2.22%higher | -0.54%lower |
| 1 year | +103%higher | -24.5%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Cathie Wood0.3% / 3.2%
Adaptive Biotechnologies only (2)
- Andreas Halvorsen1.8%
- Polen Capital team<0.1%
CRISPR Therapeutics only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Adaptive Biotechnologies / CRISPR Therapeutics). Who owns ADPT · Who owns CRSP
More on Adaptive Biotechnologies
Further comparisons
Adaptive Biotechnologies against its closest peers
CRISPR Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Adaptive Biotechnologies or CRISPR Therapeutics?
By market value, Adaptive Biotechnologies is the larger: $4.6B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, Adaptive Biotechnologies is the larger: $277M against $3.5M for CRISPR Therapeutics.
Which has the higher operating margin?
Adaptive Biotechnologies: -20.6%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Adaptive Biotechnologies and CRISPR Therapeutics?
In their latest 13F filings, Cathie Wood holds both.
Cite this page
Funkfolio, “Adaptive Biotechnologies vs CRISPR Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/adpt-vs-crsp
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.